Aug 2026· American Journal of the Medical Sciences· 0 citations· 37 references
Medicine
TL;DR
Although ASMRs and ASDRs have declined, the global burden of hepatitis B and C remains considerable, and continued efforts in vaccination, antiviral treatment, and control of key risk factors are crucial, especially in populations with a high burden.
Abstract
Background
Hepatitis B and C continue to pose significant challenges to global public health, and this study is aimed at evaluating their burden.
Methods
Leveraging data from the Global Burden of Disease 2021, we analyzed age-standardized mortality rates (ASMRs) and age-standardized disability-adjusted life year rates (ASDRs) for hepatitis B and C from 1990 to 2021 using Joinpoint regression, age-period-cohort models, and decomposition analysis. Bayesian age-period-cohort models were applied to project future trends up to 2036. Additionally, we assessed the burden attributable to modifiable risk factors and its association with socioeconomic indicators.
Results
From 1990 to 2021, the global ASMR for hepatitis B declined from 12.19 to 7.57 per 100,000, and the ASMR for hepatitis C decreased from 8.18 to 6.10 per 100,000. Despite these decreases, the absolute numbers of deaths and DALYs continued to increase, mainly driven by population growth and aging. In 2021, males carried a disproportionately higher burden of hepatitis B and C compared to females. Moreover, countries with low socioeconomic development faced a greater burden. Notably, high alcohol consumption accounted for 16.20% of hepatitis B DALYs, while drug use was responsible for 49.49% of hepatitis C DALYs. By 2036, ASMRs are projected to decline further to 5.90 per 100,000 for hepatitis B and 5.23 per 100,000 for hepatitis C.
Conclusions
Although ASMRs and ASDRs have declined, the global burden of hepatitis B and C remains considerable. Continued efforts in vaccination, antiviral treatment, and control of key risk factors are crucial, especially in populations with a high burden.
Chronic hepatitis C (CHC), including cirrhosis, remains a major global health challenge. While direct-acting antivirals have improved prognoses, barriers to diagnosis and equitable access hinder World Health Organization’s 2030 eradication target. This study systematically assessed the global burden and trends to infor...
Viral hepatitis constitutes a primary cause of liver cirrhosis and carcinoma and ranks as the second leading cause of mortality worldwide due to challenges in early detection and limited preventive measures, thereby posing a significant threat to public health. This study analyses the burden and risk factors associated...
Ji-Yuan Ren, Ran Ji, Zi-Mo Zhu et al.· Journal of Viral Hepatitis· 0 citations
Despite substantial declines in age-standardized mortality and DALY rates, absolute CRC burden in G20 countries has increased dramatically over three decades, driven by population growth and aging.
Ke Zhang, Zhi-Fei Chen· Digestive Diseases· 0 citations
The national and regional burden of hepatitis C infection in Ethiopia between 2019 and 2023 using findings from the Global Burden of Disease Study 2023 showed an increase in prevalence and incidence, and the highest prevalence was observed in the 55+ years age group.
Alemayehu Abate, Melkamnesh Azage· Canadian Journal of Gastroen...· 0 citations
Gastric cancer (GC) remains a major global health issue with high incidence and mortality. This study evaluates the global burden and health disparities of GC from 1990 to 2021 and projects trends through 2036, providing evidence for targeted control measures. The data were sourced from the 2021 Global Burden of Diseas...
Bayesian age-period-cohort projections indicate that by 2035, GC incidence is anticipated to reach 1,159,745, while the expected numbers of deaths and DALYs are forecasted to decline to 667,145 and 15,783,072, respectively, while the impact of GC in older age demographics is projected to increase significantly.
Liying Ma, Juan Ou, Zi-Jun Qiu et al.· Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.